1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > T-Cell Leukemia - Pipeline Review, H1 2015

T-Cell Leukemia - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 93 pages

T-Cell Leukemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘T-Cell Leukemia - Pipeline Review, H1 2015’, provides an overview of the T-Cell Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

T-Cell Leukemia - Pipeline Review, H1 2015
Table of Contents
Introduction 7
Global Markets Direct Report Coverage 7
T-Cell Leukemia Overview 8
Therapeutics Development 9
Pipeline Products for T-Cell Leukemia - Overview 9
Pipeline Products for T-Cell Leukemia - Comparative Analysis 10
T-Cell Leukemia - Therapeutics under Development by Companies 11
T-Cell Leukemia - Therapeutics under Investigation by Universities/Institutes 12
T-Cell Leukemia - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
T-Cell Leukemia - Products under Development by Companies 15
T-Cell Leukemia - Products under Investigation by Universities/Institutes 16
T-Cell Leukemia - Companies Involved in Therapeutics Development 17
Applied Immune Technologies Ltd 17
Astellas Pharma Inc. 18
Bristol-Myers Squibb Company 19
Celgene Corporation 20
iDD biotech SAS 21
Kyowa Hakko Kirin Co., Ltd. 22
MediGene AG 23
Nippon Kayaku Co., Ltd. 24
Pfizer Inc. 25
Pharmacyclics, Inc. 26
Sanofi 27
Stemline Therapeutics, Inc. 28
Theravectys S.A. 29
Tolero Pharmaceuticals, Inc. 30
T-Cell Leukemia - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AGS-67E - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
alemtuzumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
BMS-906024 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Cell Therapy to Target CD38 for cancer - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
IDD-003 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
INA-01 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
lenalidomide - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
MMIG-202 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
mogamulizumab - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
NK-314 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
PCI-34051 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
PF-03084014 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
SL-101 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
Synthetic Peptide for Oncology and Male health - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
THV-02 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
TP-0903 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
T-Cell Leukemia - Recent Pipeline Updates 68
T-Cell Leukemia - Dormant Projects 85
T-Cell Leukemia - Discontinued Products 86
T-Cell Leukemia - Product Development Milestones 87
Featured News and Press Releases 87
Feb 04, 2015: THERAVECTYS Obtains Orphan Drug Designation from the European Medicines Agency for Its Lentiviral Vector-Based Therapeutic Vaccine against Adult T-Cell Leukemia and Lymphoma 87
Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab 88
Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 88
Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe 89
Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 89
May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan 90
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 90
Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables
Number of Products under Development for T-Cell Leukemia, H1 2015 9
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
T-Cell Leukemia - Pipeline by Applied Immune Technologies Ltd, H1 2015 17
T-Cell Leukemia - Pipeline by Astellas Pharma Inc., H1 2015 18
T-Cell Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2015 19
T-Cell Leukemia - Pipeline by Celgene Corporation, H1 2015 20
T-Cell Leukemia - Pipeline by iDD biotech SAS, H1 2015 21
T-Cell Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 22
T-Cell Leukemia - Pipeline by MediGene AG, H1 2015 23
T-Cell Leukemia - Pipeline by Nippon Kayaku Co., Ltd., H1 2015 24
T-Cell Leukemia - Pipeline by Pfizer Inc., H1 2015 25
T-Cell Leukemia - Pipeline by Pharmacyclics, Inc., H1 2015 26
T-Cell Leukemia - Pipeline by Sanofi, H1 2015 27
T-Cell Leukemia - Pipeline by Stemline Therapeutics, Inc., H1 2015 28
T-Cell Leukemia - Pipeline by Theravectys S.A., H1 2015 29
T-Cell Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
T-Cell Leukemia Therapeutics - Recent Pipeline Updates, H1 2015 68
T-Cell Leukemia - Dormant Projects, H1 2015 85
T-Cell Leukemia - Discontinued Products, H1 2015 86

List of Figures
Number of Products under Development for T-Cell Leukemia, H1 2015 9
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Top 10 Targets, H1 2015 32
Number of Products by Stage and Top 10 Targets, H1 2015 32
Number of Products by Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 36
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37
Number of Products by Top 10 Molecule Types, H1 2015 38
Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.